Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists
The DOI matches its Crossref record; 76 of the 79 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 receptor agonists (GLP1RAs) have rapidly changed the landscape of diabetes and obesity treatment. Enthusiasm for their use is tempered with concerns regarding their risk for inducing C-cell tumors based on preclinical studies in rodents. A black-box warning from the US Food and Drug Administration recommends against using GLP1RA in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2A or 2B (MEN2), providing clear guidance regarding this cohort of patients. However, emerging data also suggest an increased incidence of differentiated thyroid cancer (DTC) in patients treated with these agents. Other studies, though, have not confirmed an association between GLP1RAs and DTC. With conflicting results concerning thyroid cancer risk, there is no clear consensus regarding the optimal approach to screening patients prior to initiating the medications and/or evaluating for thyroid cancer during GLP1RA treatment. Within the context of patient cases, this review will summarize the existing data, describe ongoing controversies, and outline future areas for research regarding thyroid cancer risk with GLP1RA use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, all GLP-1s have FDA black box warnings for a potential association with thyroid cancer and long-term data on the safety of the higher doses used for obesity treatment are not yet available [19].”
From Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US (2025) · cites this paper as [19]
Citations
Cites
Management of a Solitary Thyroid Nodule
Desforges, J. F., & Mazzaferri, E. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280807 · Cited by 1,412
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
Bansal, M. B., Patton, H. M., Morgan, T. R. M., Carr, R. M., Dranoff, J. A., & Allen, A. M. (2025) · Hepatology · doi:10.1097/hep.0000000000001608 · Cited by 192
Pearson, S. D., Whaley, C. M., & Emond, S. K. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0083 · Cited by 55
“In addition, all GLP-1s have FDA black box warnings for a potential association with thyroid cancer and long-term data on the safety of the higher doses used for obesity treatment are not yet available [19] .”
Valencia-Rincón, E., Rai, R., Chandra, V., & Wellberg, E. A. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194743 · Cited by 44
“Nonetheless, the FDA issued a warning for most GLP-1R–targeted therapies for patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome, which remains in place today (41).”
Wang, L., Zhang, L., Ma, R., Zhang, Y., Chang, Q., & Yin, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf053 · Cited by 29
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 34
“The theoretical risk requires a lifetime contraindication in patients with a personal or family history of medullary thyroid cancer (MTC) or menin-2 (Mary and Curtis 2010; Kelly and Sipos 2024).”
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Alluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“48).”
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 15
Chen, W., Wang, Y., Xie, W., Wang, J., Ji, X., Feng, C., & Zhang, X. (2025) · The FASEB Journal · doi:10.1096/fj.202500061r · Cited by 5
“10 Furthermore, combining MRAs with RAS inhibitors may increase the risk of hyperkalemia 11 and combining SGLT2 inhibitors with metformin may lead to hypoglycemic episodes.”
Injectables Pharmacotherapies for Obesity: Mechanisms, Efficacy, and Aesthetic Implications
Gomes, J. M., Ferreira, A. C. M., & Barbosa, A. D. P. (2025) · Obesities · doi:10.3390/obesities5020022 · Cited by 8
“These safety points show how important it is to check patients carefully and understand the risks before starting treatment [68].”
Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists
Temperley, H. C., & Kelly, M. E. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00062 · Cited by 3
Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide
Beshay, L. H., Makker, J., & Ahern, S. (2026) · Cureus · doi:10.7759/cureus.107836 · Cited by 2
Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer
Muscogiuri, G., Vecchio, G. D., Colangeli, L., Guglielmi, V., Sbraccia, P., & Colao, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04458-z · Cited by 1
The Risk of Hypothyroidism With the Use of GLP ‐1 Receptor Agonists in Saudi Arabia
Alfakhri, A., Almadani, O. A., Alroba, R., Alrwisan, A. A., Alshaya, O. A., & Albogami, Y. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70315
“Experimental studies have shown that GLP-1 receptors are expressed in thyroid tissue, although their functional significance remains unclear [10, 39].”
Deng, C.-X., Chen, Z.-M., Tang, Y.-X., Xi, Z.-X., Wang, S.-Y., Wu, H.-Y., Xu, B., & Xu, T.-C. (2026) · World Journal of Pharmacology · doi:10.5497/wjp.v15.i1.113080
Salama, S., Omer, E. O. E., Mahmoud, A., ElshikhIdris, M. A. M., Hussien, T. M. M., Ahmed, M., Fadulelsayed, S. O., Ibrahim, S. A. M., Mohammed, H. O. A., & Alhajri, A. H. M. (2026) · Cureus · doi:10.7759/cureus.108005 · Cited by 2
Anderson, C., Smith, R. V., & DeBiase, C. (2026) · The Laryngoscope · doi:10.1002/lary.70604
Tirzepatide: A Paradigm Shift in the Management of Type 2 Diabetes and Obesity
Sonawane, R. A., Gulave, O. K., Kale, P. A., & Rasal, P. B. (2026) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0092
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“Accordingly, current prescribing recommendations continue to emphasize cautious use and contraindication in high-risk populations, despite the absence of confirmed excess risk in human studies [151, 280–282].”
Examining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms
Rajan, L., Hofland, J., Mulugeta, E., & de Herder, W. W. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag135
Porwolik, A., Porwolik, H., Cyran, P., Szydłowski, R., Bodera, M., & Skotarski, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5185
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
GLP-1 Receptor Agonists and Obesity Related Cancers: What We Know So Far
Raja, N. P., & Kandagari, N. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01825-z
“Rodent studies demonstrated dose-and duration-dependent C-cell hyperplasia and MTC with GLP-1RA exposure, leading to boxed warnings and contra-indications in patients with a personal or family history of MTC or MEN2 [ 26, 27].”
Feng, Y., Liu, X., Zhang, X., Sun, Y., Ren, K., Qian, X., Sun, W., Li, J., & Yu, B. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122417
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Clinical Decision-Making for Incretin-Based Therapy in Neurofibromatosis Type 1
Ayar, U. D., Akurati, S., Petridis, S. F., Mejia, H., Udayakumar, V., Punjabi, N., Bernal‐Mizrachi, E., & Varghese, R. T. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.07.024
Metadata
- Authors
- Kelly, C. A., & Sipos, J. A.
- Affiliations
- University Hospitals of Cleveland (US)
- The Ohio State University Wexner Medical Center (US)
- ORCID
- Sipos, Jennifer A
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2024-10-14
- Volume
- 110
- Issue
- 6
- Pages
- e2080-e2087
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W4403398649
- Cited by
- 30
- References
- 79
- Citations by year
- 2026: 20 · 2025: 10
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Keywords
- GLP-1 receptor agonists, thyroid nodules, medullary thyroid carcinoma, multiple endocrine neoplasia type 2, differentiated thyroid cancer, thyroid cancer risk, black box warning, thyroid cancer screening, obesity treatment, diabetes treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Thyroid Neoplasms, Thyroid Nodule, Carcinoma, Neuroendocrine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.